Tumor Biology

, Volume 37, Issue 3, pp 3719–3725 | Cite as

The clinical significance of vascular endothelial growth factor in malignant ascites

Original Article

Abstract

Ascites can be caused by many kinds of diseases. Patients with undetermined ascites represent a diagnostic challenge. The aims of this study were to determine the diagnostic value of vascular endothelial growth factor (VEGF) in differentiation of malignant ascites from benign ascites and to investigate the clinical value of ascitic VEGF as an independent prognostic parameter. The study included 462 consecutive patients with malignant ascites and 550 patients with benign ascites, VEGF level in ascites were determined by a sandwich enzyme-linked immunosorbent assay. The survival rate was calculated by the Kaplan-Meier method and the log-rank test. Multivariate survival analysis was performed using the Cox hazards model. In our study, we found VEGF levels in malignant ascites (676.59 ± 303.86 pg/ml) were significantly higher than those in benign ascites (218.37 ± 98.15 pg/ml) (P < 0.001). Meanwhile, we also found that VEGF levels in malignant ascites from patients with ovarian cancer were higher than those with other cancers. Areas under the receiver operating characteristic (ROC) curves of ascitic VEGF was 0.940. At a cutoff value of 319.5 pg/ml, VEGF yielded a sensitivity of 89.2 % and a specificity of 88.4 %. Patients associated with the high-level VEGF value (≥613.38 pg/ml) in malignant ascites exhibited poor mean survival rates (8.3 ± 0.52 vs 15.11 ± 0.66 months, P < 0.001). In a multivariate Cox regression model, higher ascitic VEGF was an independent prognostic factor for overall survival. Planned subgroup analysis was performed for patients with tumor node metastasis (TNM) stage I. In the univariate analysis, only ascitic VEGF was associated with overall survival. VEGF was found to have a highly accurate sensitivity and specificity, suggesting that it could be considered as a new biomarker to differentiate malignant ascites from the benign one. The high level of VEGF value in malignant ascites may be used as an independent prognostic factor in patients with all stages of cancer.

Keywords

Ascites VEGF Differential diagnosis Prognosis 

Notes

Acknowledgments

This study was supported by a grant from the 2007 fund project of the Science and Technology research, Wuhan city, China (topic no. 200760423153).

Conflicts of interest

None

Authors’ contributions

NZ designed the study, evaluated the ELISA results, and wrote the manuscript. XGL performed the statistical analyses. WGD designed the study. JW evaluated the clinical records.

All authors read and approved the manuscript.

References

  1. 1.
    Greco AV, Mingrone G, Gasbarrini G. Free fatty acid analysis in ascitic fluid improves diagnosis in malignant abdominal tumors. Clin Chim Acta. 1995;239(1):13–22.CrossRefPubMedGoogle Scholar
  2. 2.
    McHutchison JG. Differential diagnosis of ascites. Semin Liver Dis. 1997;17(3):191–202.CrossRefPubMedGoogle Scholar
  3. 3.
    Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Parsons SL, Watson SA, Steele RJC. Malignant ascites. Br J Surg. 1996;83(1):6–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Yabushita H, Shimazu M, Noguchi M, et al. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003;10(1):89–95.PubMedGoogle Scholar
  6. 6.
    Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schmacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadduccid A, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Gentilini F, Calzolari C, Turba ME. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leuk Res. 2005;29(11):1263–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Brattstroma D, Bergpvixt M, Hesselius P, Larsson A, Lamberg K, Wernlund J, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer. 2003;37(1):57–63.CrossRefGoogle Scholar
  10. 10.
    Kozłowski M, Laudański W, Mroczko B, Szmitkowski M, Milewski R, Lapuć G. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. Adv Med Sci. 2013;58(2):227–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Werther K, Christensen IJ, Brünner N, Nielsen HJ. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol. 2000;26(7):657–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Garrison RN, Vaclin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986;203(6):644–51.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Loewenstein MS, Rittgers RA, Feinerman AE, et al. Carcinoembryonic antigen assay of ascites and detection of malignancy. Ann Intern Med. 1978;88(5):635–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29(5):369–77.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337–42.CrossRefPubMedGoogle Scholar
  16. 16.
    Gerbes AL, Jungst D. Role of cholesterol determination in ascitic fluid analysis. Hepatology. 2009;50(4):1320.CrossRefPubMedGoogle Scholar
  17. 17.
    Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.PubMedGoogle Scholar
  18. 18.
    Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285–93.CrossRefPubMedGoogle Scholar
  19. 19.
    Aslam N, Marino CR. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74(3):429–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Sherer DM, Eliakim R, Abulafia O. The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest. 2000;50(4):217–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6(4):373–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Nascimento I, Schaer R, Lemaire D, Freire S, Paule B, Carvalho S, et al. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites. APMIS. 2004;112(9):585–7.CrossRefPubMedGoogle Scholar
  24. 24.
    DongWG SXM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003;9(11):2596–600.Google Scholar
  25. 25.
    NI li. Combined detection of VEGF, ADA and LDH in differential diagnosis of benign and malignant ascites//CAI Haibin, Laboratory Medicine meeting of Zhejiang province, Hang Zhou, 2007.Google Scholar
  26. 26.
    Zhao XK. The clinical value of vascular endothelial growth factor in the diagnosis of malignant ascites. Taiyuan: Medical University of Shanxi; 2002.Google Scholar
  27. 27.
    Reb XF, Gong FL, Yao J. Investigation of vascular endothelial growth factor, collagen IV, III procollagen, hyaluronic acid and laminin in the diagnosis of in malignant ascites. Clin Focus. 2009;24(7):623–4.Google Scholar
  28. 28.
    Li Z, Chen WC, Su Y. Diagnostic value of the vascular endothelial growth factor in ascites. Chin J Pra Int Med. 2004;24(8):484–5.Google Scholar
  29. 29.
    Li Q, Dong WG. Soluble CD44 splice variants 6 and vascular endothelial growth factor in diagnosis of malignant ascites. Clin Med China. 2006;22(3):240–2.Google Scholar
  30. 30.
    Cheng D, Liang B. Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites. Med Oncol. 2012;29(2):1397–401.CrossRefPubMedGoogle Scholar
  31. 31.
    Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Cancer Sci. 1996;87(9):963–71.Google Scholar
  33. 33.
    Yamamoto S, Konishi I, Mandai M, Kuroda H, Komastu T, Nanbu K, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997;76(9):1221–7.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997;121(2):169–75.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of PathologyRenmin Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of GastroenterologyRenmin Hospital of Wuhan UniversityWuhanChina

Personalised recommendations